Duane H. Hamilton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Duane H. Hamilton has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey Schlom
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
11 shared publications - Maria del Mar Maldonado
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
10 shared publications - Maria Gracia-Hernandez
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
8 shared publications - Claudia Palena
Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
6 shared publications Bruce Huang
4 shared publications- Cecilia Larocca
Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA
4 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015228
Epigenetic plus cytokine therapy induces stem-like CD8 + T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance
Background: Checkpoint blockade (CPB) has limited efficacy in patients with colorectal cancer (CRC), warranting improved therapeutic strategies capable of remodeling the tumor microenvironment. Stem-like TCF1 + CD8 + T cells, cytotoxic CD8 + T cells, and lymphoid aggregates have been associated with CPB responsiveness, either individually or as coordinated immune hubs. Methods: We evaluated the combination of αPD-1, the class I histone deacetylase inhibitor entinostat, and the IL-15 superagonist N-803 in CPB-resistant murine CRC and breast cancer models with varying antigen presentation deficiencies. Proteomic, transcriptomic, spatial, and functional analyses were completed to identify treatment-specific immune remodeling. Translational relevance was assessed using publicly available CPB-treated cancer genomic datasets and functional assays with patient-derived peripheral blood mononuclear cells (PBMCs). Results: Triple therapy increased stem-like TCF1 + CD8 + T cells in tumor-draining lymph nodes and tumors, concomitant with increased intratumoral cytotoxic GZMB + CD8 + T cells. Therapeutic efficacy was associated with remodeling of the tumor microenvironment, uniquely marked by enrichment of intratumoral immune niches comprising TCF1 + and cytotoxic CD8 + T cells, type 1 conventional dendritic cells, and B cells, along with concerted cytokine and chemokine production. A transcriptional signature derived from triple therapy-induced immune niches predicted favorable clinical responses across multiple CPB-experienced cancer cohorts. These responses were functionally corroborated by increased markers of cytotoxicity in patient-derived PBMCs in vitro. Conclusions: Treatment with entinostat, N-803, and αPD-1 boosts anti-tumor intratumoral immune niches comprising TCF1 + CD8 + T cells. Collectively, these findings suggest that TCF1 + CD8 + T cell immune niches previously associated with αPD-1 responsiveness and lacking in non-responders, including most CRC patients, may be restored by the addition of entinostat and N-803 to αPD-1 therapy to treat αPD-1-refractory patients.
- 12 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015228
Open AccessEpigenetic plus cytokine therapy induces stem-like CD8 + T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance
Background: Checkpoint blockade (CPB) has limited efficacy in patients with colorectal cancer (CRC), warranting improved therapeutic strategies capable of remodeling the tumor microenvironment. Stem-like TCF1 + CD8 + T cells, cytotoxic CD8 + T cells, and lymphoid aggregates have been associated with CPB responsiveness, either individually or as coordinated immune hubs. Methods: We evaluated the combination of αPD-1, the class I histone deacetylase inhibitor entinostat, and the IL-15 superagonist N-803 in CPB-resistant murine CRC and breast cancer models with varying antigen presentation deficiencies. Proteomic, transcriptomic, spatial, and functional analyses were completed to identify treatment-specific immune remodeling. Translational relevance was assessed using publicly available CPB-treated cancer genomic datasets and functional assays with patient-derived peripheral blood mononuclear cells (PBMCs). Results: Triple therapy increased stem-like TCF1 + CD8 + T cells in tumor-draining lymph nodes and tumors, concomitant with increased intratumoral cytotoxic GZMB + CD8 + T cells. Therapeutic efficacy was associated with remodeling of the tumor microenvironment, uniquely marked by enrichment of intratumoral immune niches comprising TCF1 + and cytotoxic CD8 + T cells, type 1 conventional dendritic cells, and B cells, along with concerted cytokine and chemokine production. A transcriptional signature derived from triple therapy-induced immune niches predicted favorable clinical responses across multiple CPB-experienced cancer cohorts. These responses were functionally corroborated by increased markers of cytotoxicity in patient-derived PBMCs in vitro. Conclusions: Treatment with entinostat, N-803, and αPD-1 boosts anti-tumor intratumoral immune niches comprising TCF1 + CD8 + T cells. Collectively, these findings suggest that TCF1 + CD8 + T cell immune niches previously associated with αPD-1 responsiveness and lacking in non-responders, including most CRC patients, may be restored by the addition of entinostat and N-803 to αPD-1 therapy to treat αPD-1-refractory patients.
- Open Access
- 1 July 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (7) , e014518
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an aggressive disease with limited response to systemic therapies despite androgen deprivation. Immune-excluded prostate tumors are typically resistant to immunotherapy. STAR0602 is a selective bifunctional T-cell agonist composed of an antibody targeting Vβ6 and Vβ10 T-cell receptor chains fused to human interleukin-2 that selectively expands Vβ6 + CD8 + memory T cells and has demonstrated clinical activity as a monotherapy in anti-programmed death-ligand 1-resistant tumors ( NCT05592626 ). We hypothesized that combining poly ADP-ribose polymerase (PARP) inhibition with Vβ-directed T-cell activation would enhance antitumor immunity and promote polyclonal T-cell responses in immune-excluded prostate cancer. Methods: The antitumor activity of the PARP inhibitor olaparib combined with mSTAR1302, the murine surrogate of STAR0602, was evaluated in TRAMP-C2 and RM-1 prostate tumor models. Tumor growth, survival, and immune responses were assessed by flow cytometry and functional depletion studies. The role of tumor-intrinsic TRAIL-R2 signaling was evaluated using a TRAIL-R2 knockout TRAMP-C2 model, and clinical relevance was explored by assessing TRAIL-R2 expression in tumor samples from patients treated with olaparib in a Phase 2 clinical trial ( NCT02484404 ). Results: Combination therapy with olaparib and mSTAR1302 induced significant tumor regression and improved survival compared with either agent alone. Treatment increased tumor-infiltrating lymphocytes, expanded activated Vβ13 + CD4 + and Vβ13 + CD8 + T cells, reduced immunosuppressive populations, and enriched stem-like progenitor exhausted CD8 + T cells. Depletion studies demonstrated that Vβ13 + CD4 + T cells, Vβ13 + CD8 + T cells, natural killer cells, and interferon-γ were required for therapeutic efficacy. TRAIL-R2 knockout experiments demonstrated that tumor-intrinsic TRAIL-R2 signaling contributes to the antitumor activity of the combination. Mechanistically, these findings support a model in which PARP inhibition sensitizes tumors while mSTAR1302-mediated Vβ13 + T-cell expansion initiates a broader polyclonal antitumor immune response associated with antigen spreading and recognition of multiple tumor antigens and neoepitopes. Conclusions: These findings suggest that combining tumor-sensitizing therapies with selective T-cell activation may represent a broader strategy to overcome immune exclusion in solid tumors. Together, these results provide mechanistic rationale for clinical evaluation of olaparib in combination with STAR0602 in patients with mCRPC who have progressed on androgen deprivation therapy.
- 1 July 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (7) , e014518
Open AccessPARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an aggressive disease with limited response to systemic therapies despite androgen deprivation. Immune-excluded prostate tumors are typically resistant to immunotherapy. STAR0602 is a selective bifunctional T-cell agonist composed of an antibody targeting Vβ6 and Vβ10 T-cell receptor chains fused to human interleukin-2 that selectively expands Vβ6 + CD8 + memory T cells and has demonstrated clinical activity as a monotherapy in anti-programmed death-ligand 1-resistant tumors ( NCT05592626 ). We hypothesized that combining poly ADP-ribose polymerase (PARP) inhibition with Vβ-directed T-cell activation would enhance antitumor immunity and promote polyclonal T-cell responses in immune-excluded prostate cancer. Methods: The antitumor activity of the PARP inhibitor olaparib combined with mSTAR1302, the murine surrogate of STAR0602, was evaluated in TRAMP-C2 and RM-1 prostate tumor models. Tumor growth, survival, and immune responses were assessed by flow cytometry and functional depletion studies. The role of tumor-intrinsic TRAIL-R2 signaling was evaluated using a TRAIL-R2 knockout TRAMP-C2 model, and clinical relevance was explored by assessing TRAIL-R2 expression in tumor samples from patients treated with olaparib in a Phase 2 clinical trial ( NCT02484404 ). Results: Combination therapy with olaparib and mSTAR1302 induced significant tumor regression and improved survival compared with either agent alone. Treatment increased tumor-infiltrating lymphocytes, expanded activated Vβ13 + CD4 + and Vβ13 + CD8 + T cells, reduced immunosuppressive populations, and enriched stem-like progenitor exhausted CD8 + T cells. Depletion studies demonstrated that Vβ13 + CD4 + T cells, Vβ13 + CD8 + T cells, natural killer cells, and interferon-γ were required for therapeutic efficacy. TRAIL-R2 knockout experiments demonstrated that tumor-intrinsic TRAIL-R2 signaling contributes to the antitumor activity of the combination. Mechanistically, these findings support a model in which PARP inhibition sensitizes tumors while mSTAR1302-mediated Vβ13 + T-cell expansion initiates a broader polyclonal antitumor immune response associated with antigen spreading and recognition of multiple tumor antigens and neoepitopes. Conclusions: These findings suggest that combining tumor-sensitizing therapies with selective T-cell activation may represent a broader strategy to overcome immune exclusion in solid tumors. Together, these results provide mechanistic rationale for clinical evaluation of olaparib in combination with STAR0602 in patients with mCRPC who have progressed on androgen deprivation therapy.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Endogenous retroviruses (ERV) are the genetic remnants of retroviruses in which proviral sequences integrated into germline cells of our ancestors. Although the vast majority of ERV sequences have accumulated mutations over the course of human evolution, some still contain open reading frames encoding full-length retroviral proteins. These sequences are typically epigenetically silenced in healthy adult human tissues. However, epigenetic dysregulation in cancer results in aberrant expression of ERVs in multiple cancer types. Therefore, ERVs represent a class of attractive therapeutic targets in cancer due to their immunogenicity and high expression in cancer cells compared with healthy tissues. In this review, we summarize the roles of ERVs in cancer and their immunogenicity, highlight the most recent advances in ERV-targeting strategies, discuss their challenges, and examine potential combination approaches that could further enhance the antitumor efficacy of ERV-targeting vaccines.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Endogenous retroviruses (ERV) are the genetic remnants of retroviruses in which proviral sequences integrated into germline cells of our ancestors. Although the vast majority of ERV sequences have accumulated mutations over the course of human evolution, some still contain open reading frames encoding full-length retroviral proteins. These sequences are typically epigenetically silenced in healthy adult human tissues. However, epigenetic dysregulation in cancer results in aberrant expression of ERVs in multiple cancer types. Therefore, ERVs represent a class of attractive therapeutic targets in cancer due to their immunogenicity and high expression in cancer cells compared with healthy tissues. In this review, we summarize the roles of ERVs in cancer and their immunogenicity, highlight the most recent advances in ERV-targeting strategies, discuss their challenges, and examine potential combination approaches that could further enhance the antitumor efficacy of ERV-targeting vaccines.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table 4 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Preclinical studies using ERV-targeting vaccines in cancer models.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 4 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Preclinical studies using ERV-targeting vaccines in cancer models.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
The ISD within the retroviral ENV protein is conserved among ERVs from different species, as seen in murine leukemia virus (MLV), feline leukemia virus (FLV), and human ERVs, such as HERV-E clone 4-1. Expression of the retroviral ENV protein increases immunosuppression by inhibiting lymphocyte proliferation and decreasing activation of monocytes, T cells, and NK cells that could further contribute to tumor progression. Image modified from previous literature (Cianciolo et al., ref. 86. Reprinted with permission from American Association for the Advancement of Science). Created with BioRender.com. Maldonado Montalban, M. (2025) https://BioRender.com/w77o051.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
The ISD within the retroviral ENV protein is conserved among ERVs from different species, as seen in murine leukemia virus (MLV), feline leukemia virus (FLV), and human ERVs, such as HERV-E clone 4-1. Expression of the retroviral ENV protein increases immunosuppression by inhibiting lymphocyte proliferation and decreasing activation of monocytes, T cells, and NK cells that could further contribute to tumor progression. Image modified from previous literature (Cianciolo et al., ref. 86. Reprinted with permission from American Association for the Advancement of Science). Created with BioRender.com. Maldonado Montalban, M. (2025) https://BioRender.com/w77o051.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
ERV protein expression in multiple human cancer types.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
ERV protein expression in multiple human cancer types.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Percentages of ERV sequences expressed in different cancer types according to CancerHERVdb database (43).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Percentages of ERV sequences expressed in different cancer types according to CancerHERVdb database (43).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Immune responses against ERVs in patients with cancer.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Immune responses against ERVs in patients with cancer.
- Open Access
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 13 (6) , 792-803
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Endogenous retroviruses (ERV) are the genetic remnants of retroviruses in which proviral sequences integrated into germline cells of our ancestors. Although the vast majority of ERV sequences have accumulated mutations over the course of human evolution, some still contain open reading frames encoding full-length retroviral proteins. These sequences are typically epigenetically silenced in healthy adult human tissues. However, epigenetic dysregulation in cancer results in aberrant expression of ERVs in multiple cancer types. Therefore, ERVs represent a class of attractive therapeutic targets in cancer due to their immunogenicity and high expression in cancer cells compared with healthy tissues. In this review, we summarize the roles of ERVs in cancer and their immunogenicity, highlight the most recent advances in ERV-targeting strategies, discuss their challenges, and examine potential combination approaches that could further enhance the antitumor efficacy of ERV-targeting vaccines.
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 13 (6) , 792-803
Open AccessCombination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer
Endogenous retroviruses (ERV) are the genetic remnants of retroviruses in which proviral sequences integrated into germline cells of our ancestors. Although the vast majority of ERV sequences have accumulated mutations over the course of human evolution, some still contain open reading frames encoding full-length retroviral proteins. These sequences are typically epigenetically silenced in healthy adult human tissues. However, epigenetic dysregulation in cancer results in aberrant expression of ERVs in multiple cancer types. Therefore, ERVs represent a class of attractive therapeutic targets in cancer due to their immunogenicity and high expression in cancer cells compared with healthy tissues. In this review, we summarize the roles of ERVs in cancer and their immunogenicity, highlight the most recent advances in ERV-targeting strategies, discuss their challenges, and examine potential combination approaches that could further enhance the antitumor efficacy of ERV-targeting vaccines.
- Open Access
- 13 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011378
Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
Background Endogenous retroviruses (ERVs) are remnants of retrovirus germline infections that occurred over the course of evolution and constitute between 5% and 8% of the human genome. While ERVs tend to be epigenetically silenced in normal adult human tissues, they are often overexpressed in carcinomas and may represent novel immunotherapeutic targets. This study characterizes the ERV envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine. Methods The expression of ERVMER34-1 in multiple healthy adult and cancer tissues was assessed, as was its immunogenicity, to ascertain whether specific T cells could lyse human carcinoma cell lines expressing ERVMER34-1. Furthermore, the ability of a rationally designed ERVMER34-1-targeted therapeutic vaccine to induce tumor clearance in two murine carcinoma models expressing ERVMER34-1 was examined either as a monotherapy or in combination with anti-programmed cell death protein-1/programmed death-ligand 1 monoclonal antibody (mAb) or the interleukin-15 superagonist N-803. Results The ERVMER34-1 protein was shown to be overexpressed in 232/376 of human carcinomas analyzed while being absent in most healthy adult tissues. High levels of ERVMER34-1 RNA expression associate with decreased survival in uveal melanoma, adenoid cystic, and head and neck carcinomas. ERVMER34-1-specific T cells were detected in peripheral blood mononuclear cells (PBMCs) of patients with cancer but not healthy donors following an overnight stimulation. However, reactive T cells are readily expanded from both healthy donor and patient with cancer PBMCs following a 7- day in vitro stimulation. Furthermore, ERVMER34-1-specific T cells selectively kill human carcinoma cell lines expressing ERVMER34-1. A novel, rationally designed, therapeutic cancer vaccine targeting ERVMER34-1 mediated tumor control in established syngeneic murine tumors expressing the full-length ERVMER34-1 protein. When combined with checkpoint blockade, the vaccine promoted expansion of neoepitope-reactive T cells whose function was further enhanced when combined with N-803. This expansion of neoepitope-reactive T cells was associated with tumor control. Conclusions This study reveals the potential of a vaccine that targets the retroviral envelope protein ERVMER34-1 and supports its continued development toward clinical testing as a new class of therapeutic cancer vaccine.
- 13 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011378
Open AccessCombination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
Background Endogenous retroviruses (ERVs) are remnants of retrovirus germline infections that occurred over the course of evolution and constitute between 5% and 8% of the human genome. While ERVs tend to be epigenetically silenced in normal adult human tissues, they are often overexpressed in carcinomas and may represent novel immunotherapeutic targets. This study characterizes the ERV envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine. Methods The expression of ERVMER34-1 in multiple healthy adult and cancer tissues was assessed, as was its immunogenicity, to ascertain whether specific T cells could lyse human carcinoma cell lines expressing ERVMER34-1. Furthermore, the ability of a rationally designed ERVMER34-1-targeted therapeutic vaccine to induce tumor clearance in two murine carcinoma models expressing ERVMER34-1 was examined either as a monotherapy or in combination with anti-programmed cell death protein-1/programmed death-ligand 1 monoclonal antibody (mAb) or the interleukin-15 superagonist N-803. Results The ERVMER34-1 protein was shown to be overexpressed in 232/376 of human carcinomas analyzed while being absent in most healthy adult tissues. High levels of ERVMER34-1 RNA expression associate with decreased survival in uveal melanoma, adenoid cystic, and head and neck carcinomas. ERVMER34-1-specific T cells were detected in peripheral blood mononuclear cells (PBMCs) of patients with cancer but not healthy donors following an overnight stimulation. However, reactive T cells are readily expanded from both healthy donor and patient with cancer PBMCs following a 7- day in vitro stimulation. Furthermore, ERVMER34-1-specific T cells selectively kill human carcinoma cell lines expressing ERVMER34-1. A novel, rationally designed, therapeutic cancer vaccine targeting ERVMER34-1 mediated tumor control in established syngeneic murine tumors expressing the full-length ERVMER34-1 protein. When combined with checkpoint blockade, the vaccine promoted expansion of neoepitope-reactive T cells whose function was further enhanced when combined with N-803. This expansion of neoepitope-reactive T cells was associated with tumor control. Conclusions This study reveals the potential of a vaccine that targets the retroviral envelope protein ERVMER34-1 and supports its continued development toward clinical testing as a new class of therapeutic cancer vaccine.